Treatment Approaches for Therapy-Related AML, MDS Based on Mutation Profiles

Phase 2 data support the potential of revumenib to advance the standard of care for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

This study conducted within the phase 3 AML17 and AML19 trials revealed an OS rate of 69% in patients monitored for MRD and 58% in those not monitored.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.